Adagene (ADAG) Projected to Post Earnings on Monday

Adagene (NASDAQ:ADAG - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Adagene to post earnings of ($0.33) per share for the quarter.

Adagene Trading Down 6.6 %

ADAG traded down $0.11 during trading on Friday, hitting $1.56. The company had a trading volume of 22,886 shares, compared to its average volume of 60,084. Adagene has a one year low of $1.39 and a one year high of $3.58. The firm's 50-day moving average price is $1.87 and its 200 day moving average price is $2.18.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ADAG shares. HC Wainwright boosted their price target on Adagene from $5.00 to $8.00 and gave the company a "buy" rating in a report on Monday, January 27th. Morgan Stanley cut Adagene from an "overweight" rating to an "equal weight" rating in a research note on Friday, January 31st.

About Adagene

Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.